Zheng Huang

TL;DR: The role of PDE4 inhibitors in modulating cytokines, lipid mediators and in mucociliary clearance, along with clinical efficacy in asthma and/or COPD demonstrated with roflumilast and cilomilast, suggest a broad anti-inflammatory spectrum for these compounds.

TL;DR: It is shown that specific inhibition of PDE4 preferentially blocks the production of Th1 versus Th2 effector cytokines in vitro and rolipram and L-826,141 are potent inhibitors of CD3-plus CD28-stimulated IL-2 production in naive human T cells.

TL;DR: It is demonstrated that cofactor binding to PDE4 is responsible for eliciting its high-affinity interaction with cAMP and the activation of catalysis.

TL;DR: It is shown here that the inhibition of protein-tyrosine phosphatases (PTPs) by alendronate in the presence of calcium followed first-order kinetic behavior, and kinetic parameters for the process were determined.

TL;DR: A SAR study on the tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors related to 1 is described in this paper, where the binding affinity of these compounds for the human ether-a-go-go related gene (hERG) potassium channel (an in vitro measure for the potential to cause QTc prolongation) was assessed.